Abstract Details

Title Identifying Factors Pertaining to Migraine-Related Stigma from a Novel Question Set: Results of the OVERCOME (US) study

Topic Headache

Presentation(s) S4 - Hot Topics in Headache Medicine (1:00 PM-1:12 PM)

Poster/Presentation
Number 001

Background

Disease-related internalized stigma involves an individual’s beliefs about how others view their disease. The current study evaluated the factor structure of belief statements regarding an individual’s beliefs regarding how others view them due to their having migraine.

Objective

Identify factors pertaining to migraine-related internalized stigma derived from a set of questions regarding an individual’s beliefs of how others view them and their migraine.

Design/Methods

Data were pooled from the 2018-2020 cohorts of the OVERCOME study, a web-based survey conducted in a representative US sample (n= 61,935). Respondents with migraine were identified via validated migraine diagnostic screener based on ICHD-3 criteria (95%) and/or a self-reported medical-diagnosis of migraine (58%). The 12-item question set was developed by clinical experts and from patient interviews. The stem for each question was “How often have you felt that others viewed your migraine or severe headache…?” with response options 1 (Never) to 5 (Very Often). Exploratory Factor Analysis (EFA) using an oblique rotation (Promax) was conducted.

Results

The sample had a mean age of 41.7 years, 74% were female, 89% had episodic migraine, and 43% had at least moderate migraine-related disability (MIDAS >11). EFA suggested two factors based on eigenvalue > 1 regarding an individual’s belief regarding how others view them/their migraine. Factor loadings >0.60 were considered significant for inclusion. One factor, termed “Secondary Gain”, consists of 8 questions regarding others believing the individual uses migraine to their advantage (e.g., “get out of…commitments”, “get attention”). The second factor, termed “Minimizing Disease Burden”, consists of 4 questions regarding others’ lacking understanding of migraine’s impact (e.g., “with a lack of understanding…”, “an easily treatable condition”). These factors were consistent when segmenting respondents by monthly headache days or sex.

Conclusions

EFA suggests two factors regarding an individual’s belief of how others view them/their migraine that may serve to assess migraine-related internalized stigma.

Authors/Disclosures
Robert E. Shapiro, MD, PhD, FAAN (Larner College of Medicine, University of Vermont) PRESENTER	Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Shapiro has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for EEOC.
Robert A. Nicholson, PhD (Eli Lilly & Company)	Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
Michael L. Reed, PhD (Vedanta Research)	The institution of Dr. Reed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Reed has received research support from Allergan. The institution of Dr. Reed has received research support from Dr Reddy's Labs/Promius. The institution of Dr. Reed has received research support from Allay Lamp. Dr. Reed has a non-compensated relationship as a Research Analyst with National Headache Foundation that is relevant to AAN interests or activities.
Dawn C. Buse, PhD (Dawn C. Buse, PhD)	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Eva J. Muenzel, MD, PhD (Eli Lilly & Co)	Dr. Muenzel has received personal compensation for serving as an employee of Eli Lilly and Company.
Sait Ashina, MD (Beth Israel Deaconess Medical Center, Harvard Medical School)	Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer.
Eric Pearlman, MD	Dr. Pearlman has received personal compensation for serving as an employee of Eli Lilly and Co. Dr. Pearlman has received stock or an ownership interest from Eli Lilly and Co.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.